View Financial HealthaXichem 배당 및 자사주 매입배당 기준 점검 0/6aXichem 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.4%자사주 매입 수익률총 주주 수익률-0.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • Jan 15aXichem AB Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance SupplementaXichem AB announced the formal publication of its latest clinical trial, "Acute phenylcapsaicin supplementation improves exercise performance in CrossFit trained adults", in the Journal of the International Society of Sports Nutrition. Following the release of preliminary findings in March 2025, this final peer-reviewed publication provides the definitive scientific foundation for aXivite (phenylcapsaicin) in the elite sports and high-intensity functional fitness sectors. The randomized, triple-blind, placebo-controlled crossover trial, conducted by Dr. Pablo Jiménez Martínez and his team in Spain, examined 50 trained CrossFit athletes (25 male, 25 female). The results demonstrate that a single 2.5 mg dose of aXivite delivers significant physiological advantages: supplemented athletes achieved higher loads and repetition counts in deep squats at 70% 1RM; aXivite enabled participants to maintain weightlifting performance throughout grueling rounds, particularly in the final stages of the workout where fatigue typically peaks; data showed a statistically significant reduction in Delayed-Onset Muscle Soreness at both 24 and 48 hours post-exercise, allowing for faster returns to peak training capacity. This publication marks the latest milestone in a calculated development trajectory. aXichem has systematically built a scientific dossier for aXivite: in 2021, establishing metabolic bioequivalence to natural capsaicin with superior bioavailability and early gut health validation; in 2022-2023, validating metabolic support and weight management, followed by resistance training and aerobic capacity breakthroughs; in 2025, defining the high-intensity performance category through this definitive CrossFit study. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.공지 • Dec 01+ 5 more updatesaXichem AB, Annual General Meeting, Jun 17, 2026aXichem AB, Annual General Meeting, Jun 17, 2026.공지 • May 17aXichem AB, Annual General Meeting, Jun 18, 2025aXichem AB, Annual General Meeting, Jun 18, 2025, at 10:00 W. Europe Standard Time. Location: at the companys offices at sodergatan 26, malmo Sweden공지 • Jan 21+ 5 more updatesaXichem AB to Report Fiscal Year 2024 Results on Feb 27, 2025aXichem AB announced that they will report fiscal year 2024 results on Feb 27, 2025Reported Earnings • Aug 28Second quarter 2024 earnings released: kr0.032 loss per share (vs kr0.25 loss in 2Q 2023)Second quarter 2024 results: kr0.032 loss per share (improved from kr0.25 loss in 2Q 2023). Revenue: kr6.13m (up kr5.44m from 2Q 2023). Net loss: kr1.28m (loss narrowed 77% from 2Q 2023).공지 • May 23aXichem AB, Annual General Meeting, Jun 19, 2024aXichem AB, Annual General Meeting, Jun 19, 2024, at 10:00 W. Europe Standard Time. Location: in the company`s premises, sodergatan 26, malmo SwedenNew Risk • Apr 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr21m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$165k). Market cap is less than US$10m (€5.56m market cap, or US$5.90m).공지 • Mar 28aXichem AB has completed a Composite Units Offering in the amount of SEK 28.213935 million.aXichem AB has completed a Composite Units Offering in the amount of SEK 28.213935 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 3,761,858 Price\Range: SEK 7.5 Transaction Features: Rights Offering공지 • Mar 13OmneDiem Launches Two New ProductsaXichem AB (publ), announced that the provider of dietary supplements OmneDiemis launching two new products, formulated with aXichem's innovative ingredient aXivite, targeting the United States market. These launches represent an expansion of aXivite's applications in the fitness and wellness sectors, underscoring aXichem's commitment to broadening its global market presence and customer base. Body6, a bodybuilding and fitness brand, is set to bring important innovations in the market with the introduction of its Ready-To-Drink (RTD) pre-workout supplement powered by aXichem's aXivite. This innovative product is specifically designed to meet the needs of fitness enthusiasts and bodybuilders, offering an unparalleled boost in performance and energy. Body6 will leverage its partnership with Planet Fitness to make the pre-workout supplement accessible to a wide audience. Additionally, Body6 will feature the pre-workout and its Thermogenic Fat Management product at major national and regional fitness and bodybuilding events, including the prestigious Arnold Classic. OmneDiem is set to introduce a new product in the e-commerce and retail sectors with the launch of MaxRep Elite, a cutting-edge supplement designed to elevate workout performance and endurance. Available through various e-commerce platforms, distributors, retailers, and a network of fitness-oriented health care practitioners, MaxRep Elite aim to become the go-to choice for individuals seeking to maximize their workout potential and achieve their fitness goals.Reported Earnings • Mar 06Full year 2023 earnings released: kr1.03 loss per share (vs kr1.04 loss in FY 2022)Full year 2023 results: kr1.03 loss per share. Net loss: kr20.8m (loss widened 21% from FY 2022).Reported Earnings • Nov 24Third quarter 2023 earnings released: kr0.21 loss per share (vs kr0.32 loss in 3Q 2022)Third quarter 2023 results: kr0.21 loss per share (improved from kr0.32 loss in 3Q 2022). Revenue: kr328.0k (up 25% from 3Q 2022). Net loss: kr4.54m (loss narrowed 14% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 25First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.21 loss in 1Q 2022)First quarter 2023 results: kr0.29 loss per share (further deteriorated from kr0.21 loss in 1Q 2022). Net loss: kr4.76m (loss widened 34% from 1Q 2022). Revenue is forecast to grow 126% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 06Full year 2022 earnings released: kr1.04 loss per share (vs kr0.92 loss in FY 2021)Full year 2022 results: kr1.04 loss per share (further deteriorated from kr0.92 loss in FY 2021). Revenue: kr5.22m (up 20% from FY 2021). Net loss: kr17.3m (loss widened 14% from FY 2021). Revenue is forecast to grow 109% p.a. on average during the next 2 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.공지 • Feb 07aXichem AB to Report Fiscal Year 2022 Final Results on May 26, 2023aXichem AB announced that they will report fiscal year 2022 final results on May 26, 2023Reported Earnings • Nov 25Third quarter 2022 earnings released: kr0.32 loss per share (vs kr0.18 loss in 3Q 2021)Third quarter 2022 results: kr0.32 loss per share (further deteriorated from kr0.18 loss in 3Q 2021). Net loss: kr5.25m (loss widened 75% from 3Q 2021). Revenue is forecast to grow 125% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.공지 • Nov 24+ 4 more updatesaXichem AB to Report Q3, 2023 Results on Nov 22, 2023aXichem AB announced that they will report Q3, 2023 results on Nov 22, 2023Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering aXichem expects the company to break even for the first time. New forecast suggests the company will make a profit of kr32.0m in 2024. Average annual earnings growth of 113% is required to achieve expected profit on schedule.Reported Earnings • Aug 28Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.24 loss in 2Q 2021)Second quarter 2022 results: kr0.32 loss per share (down from kr0.24 loss in 2Q 2021). Revenue: kr702.0k (up kr642.0k from 2Q 2021). Net loss: kr5.20m (loss widened 33% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 26First quarter 2022 earnings released: kr0.21 loss per share (vs kr0.20 loss in 1Q 2021)First quarter 2022 results: kr0.21 loss per share (down from kr0.20 loss in 1Q 2021). Revenue: kr538.0k (up kr486.0k from 1Q 2021). Net loss: kr3.56m (loss widened 13% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Jan Gustavsson was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Feb 18Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr0.92 loss per share (down from kr0.85 loss in FY 2020). Net loss: kr15.1m (loss widened 12% from FY 2020). Revenue exceeded analyst estimates by 45%. Over the next year, revenue is forecast to grow 1,027%, compared to a 6.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 22First quarter 2021 earnings released: kr0.20 loss per share (vs kr0.19 loss in 1Q 2020)First quarter 2021 results: Net loss: kr3.15m (loss widened 2.2% from 1Q 2020).공지 • Mar 13+ 3 more updatesaXichem AB to Report Q1, 2021 Results on May 20, 2021aXichem AB announced that they will report Q1, 2021 results on May 20, 2021Is New 90 Day High Low • Feb 19New 90-day low: €4.00The company is down 18% from its price of €4.89 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: €4.46The company is down 3.0% from its price of €4.60 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 28% over the same period.공지 • Nov 25aXichem Signs Agreement with BART Regarding Distribution and Sales of aXivite® in PolandaXichem AB (publ), has signed a marketing, sales and distribution agreement with the Polish company Bart Spólka Sp.k. Under the agreement BART has the exclusive right to distribute and sell aXichem's capsaicin analogue product, aXivite, on the Polish market. Entering this the agreement with BART aXichem has added yet another well-established distributor in the food supplement and nutrition segment in Europe. BART not only has the sales and distribution knowledge, but also, within its organization, through two innovative subsidiaries, resources in production and product development.Is New 90 Day High Low • Sep 23New 90-day low: €4.40The company is down 25% from its price of €5.86 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A6X 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A6X 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장aXichem 배당 수익률 vs 시장A6X의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A6X)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.6%업계 평균 (Chemicals)3.8%분석가 예측 (A6X) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A6X 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A6X 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A6X 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A6X 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/07 17:29종가2026/05/07 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스aXichem AB는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Johan SvantessonRedeye
공지 • Jan 15aXichem AB Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance SupplementaXichem AB announced the formal publication of its latest clinical trial, "Acute phenylcapsaicin supplementation improves exercise performance in CrossFit trained adults", in the Journal of the International Society of Sports Nutrition. Following the release of preliminary findings in March 2025, this final peer-reviewed publication provides the definitive scientific foundation for aXivite (phenylcapsaicin) in the elite sports and high-intensity functional fitness sectors. The randomized, triple-blind, placebo-controlled crossover trial, conducted by Dr. Pablo Jiménez Martínez and his team in Spain, examined 50 trained CrossFit athletes (25 male, 25 female). The results demonstrate that a single 2.5 mg dose of aXivite delivers significant physiological advantages: supplemented athletes achieved higher loads and repetition counts in deep squats at 70% 1RM; aXivite enabled participants to maintain weightlifting performance throughout grueling rounds, particularly in the final stages of the workout where fatigue typically peaks; data showed a statistically significant reduction in Delayed-Onset Muscle Soreness at both 24 and 48 hours post-exercise, allowing for faster returns to peak training capacity. This publication marks the latest milestone in a calculated development trajectory. aXichem has systematically built a scientific dossier for aXivite: in 2021, establishing metabolic bioequivalence to natural capsaicin with superior bioavailability and early gut health validation; in 2022-2023, validating metabolic support and weight management, followed by resistance training and aerobic capacity breakthroughs; in 2025, defining the high-intensity performance category through this definitive CrossFit study. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.
공지 • Dec 01+ 5 more updatesaXichem AB, Annual General Meeting, Jun 17, 2026aXichem AB, Annual General Meeting, Jun 17, 2026.
공지 • May 17aXichem AB, Annual General Meeting, Jun 18, 2025aXichem AB, Annual General Meeting, Jun 18, 2025, at 10:00 W. Europe Standard Time. Location: at the companys offices at sodergatan 26, malmo Sweden
공지 • Jan 21+ 5 more updatesaXichem AB to Report Fiscal Year 2024 Results on Feb 27, 2025aXichem AB announced that they will report fiscal year 2024 results on Feb 27, 2025
Reported Earnings • Aug 28Second quarter 2024 earnings released: kr0.032 loss per share (vs kr0.25 loss in 2Q 2023)Second quarter 2024 results: kr0.032 loss per share (improved from kr0.25 loss in 2Q 2023). Revenue: kr6.13m (up kr5.44m from 2Q 2023). Net loss: kr1.28m (loss narrowed 77% from 2Q 2023).
공지 • May 23aXichem AB, Annual General Meeting, Jun 19, 2024aXichem AB, Annual General Meeting, Jun 19, 2024, at 10:00 W. Europe Standard Time. Location: in the company`s premises, sodergatan 26, malmo Sweden
New Risk • Apr 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr21m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$165k). Market cap is less than US$10m (€5.56m market cap, or US$5.90m).
공지 • Mar 28aXichem AB has completed a Composite Units Offering in the amount of SEK 28.213935 million.aXichem AB has completed a Composite Units Offering in the amount of SEK 28.213935 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 3,761,858 Price\Range: SEK 7.5 Transaction Features: Rights Offering
공지 • Mar 13OmneDiem Launches Two New ProductsaXichem AB (publ), announced that the provider of dietary supplements OmneDiemis launching two new products, formulated with aXichem's innovative ingredient aXivite, targeting the United States market. These launches represent an expansion of aXivite's applications in the fitness and wellness sectors, underscoring aXichem's commitment to broadening its global market presence and customer base. Body6, a bodybuilding and fitness brand, is set to bring important innovations in the market with the introduction of its Ready-To-Drink (RTD) pre-workout supplement powered by aXichem's aXivite. This innovative product is specifically designed to meet the needs of fitness enthusiasts and bodybuilders, offering an unparalleled boost in performance and energy. Body6 will leverage its partnership with Planet Fitness to make the pre-workout supplement accessible to a wide audience. Additionally, Body6 will feature the pre-workout and its Thermogenic Fat Management product at major national and regional fitness and bodybuilding events, including the prestigious Arnold Classic. OmneDiem is set to introduce a new product in the e-commerce and retail sectors with the launch of MaxRep Elite, a cutting-edge supplement designed to elevate workout performance and endurance. Available through various e-commerce platforms, distributors, retailers, and a network of fitness-oriented health care practitioners, MaxRep Elite aim to become the go-to choice for individuals seeking to maximize their workout potential and achieve their fitness goals.
Reported Earnings • Mar 06Full year 2023 earnings released: kr1.03 loss per share (vs kr1.04 loss in FY 2022)Full year 2023 results: kr1.03 loss per share. Net loss: kr20.8m (loss widened 21% from FY 2022).
Reported Earnings • Nov 24Third quarter 2023 earnings released: kr0.21 loss per share (vs kr0.32 loss in 3Q 2022)Third quarter 2023 results: kr0.21 loss per share (improved from kr0.32 loss in 3Q 2022). Revenue: kr328.0k (up 25% from 3Q 2022). Net loss: kr4.54m (loss narrowed 14% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 25First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.21 loss in 1Q 2022)First quarter 2023 results: kr0.29 loss per share (further deteriorated from kr0.21 loss in 1Q 2022). Net loss: kr4.76m (loss widened 34% from 1Q 2022). Revenue is forecast to grow 126% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 06Full year 2022 earnings released: kr1.04 loss per share (vs kr0.92 loss in FY 2021)Full year 2022 results: kr1.04 loss per share (further deteriorated from kr0.92 loss in FY 2021). Revenue: kr5.22m (up 20% from FY 2021). Net loss: kr17.3m (loss widened 14% from FY 2021). Revenue is forecast to grow 109% p.a. on average during the next 2 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
공지 • Feb 07aXichem AB to Report Fiscal Year 2022 Final Results on May 26, 2023aXichem AB announced that they will report fiscal year 2022 final results on May 26, 2023
Reported Earnings • Nov 25Third quarter 2022 earnings released: kr0.32 loss per share (vs kr0.18 loss in 3Q 2021)Third quarter 2022 results: kr0.32 loss per share (further deteriorated from kr0.18 loss in 3Q 2021). Net loss: kr5.25m (loss widened 75% from 3Q 2021). Revenue is forecast to grow 125% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.
공지 • Nov 24+ 4 more updatesaXichem AB to Report Q3, 2023 Results on Nov 22, 2023aXichem AB announced that they will report Q3, 2023 results on Nov 22, 2023
Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering aXichem expects the company to break even for the first time. New forecast suggests the company will make a profit of kr32.0m in 2024. Average annual earnings growth of 113% is required to achieve expected profit on schedule.
Reported Earnings • Aug 28Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.24 loss in 2Q 2021)Second quarter 2022 results: kr0.32 loss per share (down from kr0.24 loss in 2Q 2021). Revenue: kr702.0k (up kr642.0k from 2Q 2021). Net loss: kr5.20m (loss widened 33% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 26First quarter 2022 earnings released: kr0.21 loss per share (vs kr0.20 loss in 1Q 2021)First quarter 2022 results: kr0.21 loss per share (down from kr0.20 loss in 1Q 2021). Revenue: kr538.0k (up kr486.0k from 1Q 2021). Net loss: kr3.56m (loss widened 13% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Jan Gustavsson was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 18Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr0.92 loss per share (down from kr0.85 loss in FY 2020). Net loss: kr15.1m (loss widened 12% from FY 2020). Revenue exceeded analyst estimates by 45%. Over the next year, revenue is forecast to grow 1,027%, compared to a 6.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 22First quarter 2021 earnings released: kr0.20 loss per share (vs kr0.19 loss in 1Q 2020)First quarter 2021 results: Net loss: kr3.15m (loss widened 2.2% from 1Q 2020).
공지 • Mar 13+ 3 more updatesaXichem AB to Report Q1, 2021 Results on May 20, 2021aXichem AB announced that they will report Q1, 2021 results on May 20, 2021
Is New 90 Day High Low • Feb 19New 90-day low: €4.00The company is down 18% from its price of €4.89 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: €4.46The company is down 3.0% from its price of €4.60 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 28% over the same period.
공지 • Nov 25aXichem Signs Agreement with BART Regarding Distribution and Sales of aXivite® in PolandaXichem AB (publ), has signed a marketing, sales and distribution agreement with the Polish company Bart Spólka Sp.k. Under the agreement BART has the exclusive right to distribute and sell aXichem's capsaicin analogue product, aXivite, on the Polish market. Entering this the agreement with BART aXichem has added yet another well-established distributor in the food supplement and nutrition segment in Europe. BART not only has the sales and distribution knowledge, but also, within its organization, through two innovative subsidiaries, resources in production and product development.
Is New 90 Day High Low • Sep 23New 90-day low: €4.40The company is down 25% from its price of €5.86 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period.